Deniz Koksal1, Ozge Safak2, Aysenaz Ozcan2, Yetkin Agackiran3, Hakan Erturk4, Gokturk Findik5. 1. Department of Chest Diseases, Hacettepe University Medical Faculty, Ankara, Turkey dckoksal@gmail.com. 2. Department of Chest Diseases, Ataturk Chest Diseases and Chest Surgery Education and Research Hospital, Ankara, Turkey. 3. Department of Pathology, Ataturk Education and Research Hospital, Ankara, Turkey. 4. Department of Radiology, Ataturk Chest Diseases and Chest Surgery Education and Research Hospital, Ankara, Turkey. 5. Department of Chest Surgery, Ataturk Chest Diseases and Chest Surgery Education and Research Hospital, Ankara, Turkey.
Abstract
AIM: Malignant pleural mesothelioma (MPM) increases the risk of thromboembolic events (TEEs). In this retrospective study, we aimed to determine the rate of TEEs in MPM and investigate its relationship with the presence of thrombocytosis, the disease stage, and the tumor histopathology. METHODS: The study included 178 patients who were histopathologically diagnosed as MPM between the years January 2008 and June 2014. RESULTS: The mean age was 58.7 ± 11.8 years, and the median follow-up time was 8 months. Seventy-one patients (39.9%) had thrombocytosis (>350 × 10(3)/mL). In total, 14 (7.9%) TEEs were identified: 6 (3.4%) pulmonary thromboembolism, 6 (3.4%) deep venous thrombosis, and 2 (1.1%) myocardial infarctions. Although 5 (2.8%) of the TEEs preceded the diagnosis of MPM, 1 (0.6%) occurred simultaneously with the diagnosis of MPM and 8 (4.5%) followed the diagnosis of MPM. Thromboembolic event rates were not statistically different based on the presence of thrombocytosis (P = .51), disease stage (P = .14), and histopathology (P = .38). CONCLUSION: The rate of TEEs was 7.9%. Presence of thrombocytosis, disease stage, and histopathology did not affect the incidence of TEEs.
AIM: Malignant pleural mesothelioma (MPM) increases the risk of thromboembolic events (TEEs). In this retrospective study, we aimed to determine the rate of TEEs in MPM and investigate its relationship with the presence of thrombocytosis, the disease stage, and the tumor histopathology. METHODS: The study included 178 patients who were histopathologically diagnosed as MPM between the years January 2008 and June 2014. RESULTS: The mean age was 58.7 ± 11.8 years, and the median follow-up time was 8 months. Seventy-one patients (39.9%) had thrombocytosis (>350 × 10(3)/mL). In total, 14 (7.9%) TEEs were identified: 6 (3.4%) pulmonary thromboembolism, 6 (3.4%) deep venous thrombosis, and 2 (1.1%) myocardial infarctions. Although 5 (2.8%) of the TEEs preceded the diagnosis of MPM, 1 (0.6%) occurred simultaneously with the diagnosis of MPM and 8 (4.5%) followed the diagnosis of MPM. Thromboembolic event rates were not statistically different based on the presence of thrombocytosis (P = .51), disease stage (P = .14), and histopathology (P = .38). CONCLUSION: The rate of TEEs was 7.9%. Presence of thrombocytosis, disease stage, and histopathology did not affect the incidence of TEEs.
Authors: Luis E De León; Carlos E Bravo-Iñiguez; Sam Fox; Jeffrey Tarascio; Samuel Freyaldenhoven; Moshe Lapidot; Michael T Jaklitsch; Raphael Bueno Journal: J Thorac Cardiovasc Surg Date: 2020-01-30 Impact factor: 5.209